Deal of the Day — limited-time pharmacy picks!
Sprycel 70mg Tablet

Sprycel 70mg Tablet

Prescription requiredRx Required

Salt Composition: Dasatinib

Expiry Date: 01/2028

Special offer

Price on Request

Price on Request

Inclusive of all taxes

▼

60 tablet

About The Product

Blood Cancer

The Sprycel 70mg Tablet is used to treat chronic myeloid leukemia, or blood cancer. Patients who are unable to take other leukemia medications due to adverse effects or whose disease cannot be treated with them are treated with it. It is a member of the class of drugs called protein-tyrosine kinase inhibitors.

This medication contains Dasatinib 70mg and functions by preventing the abnormal protein that instructs cancer cells to proliferate from doing its job. It is crucial that you take this medication exactly as directed by your physician. While taking this medication, blood cell counts must be closely monitored.

Uses

Blood cancer (Chronic myeloid leukaemia)


Side Effects

Sprycel may cause some common side effects. Before starting treatment, discuss the risks and benefits of Sprycel tablets, as well as your medical history, with your doctor. 

  • Bleeding gums  
  • Constipation  
  • Coughing up blood  
  • Body pain  
  • Dizziness  
  • Weight gain  
  • Irregular heartbeat  
  • Sore throat 
  • Headache  
  • Nasal congestion  
  • Anemia  
  • Fatigue  
  • Nausea  
  • Infection  
  • Low blood platelets 

Dosage and Administration

  • Take Sprycel 70mg Tablet as prescribed by your doctor.
  • Do not stop or skip your regular dosing schedule.
  • In case of an overdose of Sprycel tablets, the doctor will provide emergency medical treatment.

Mechanism of action

Acute lymphoblastic leukemia (ALL) and chronic myeloid leukemia (CML) cell lines that overexpressed BCR-ABL were reduced in their proliferation by dasatinib. Dasatinib successfully overcame imatinib resistance caused by mutations in the BCR-ABL kinase domain, activation of alternative signaling pathways involving the SRC family kinases (LYN, HCK), and overexpression of multi-drug resistance genes under the assay conditions.

The effects of this medication can be seen one to six hours after oral consumption.

Safety Advice

Alcohol
It is advisable not to consume alcohol while taking this medicine.
Pregnancy
Do not take Sprycel 70mg Tablet without consulting the doctor, in case of pregnancy.
Breast Feeding
Without a doctor's consultation, do not take this medicine if you're breastfeeding.
Driving
It is advisable not to drive or operate heavy machinery, you may feel dizzy as one of the side effects of the medicine.
Kidney
Do not consume Sprycel 70mg Tablet without a doctor's consultation in case of kidney problems.
Liver
Share your medical history with the doctor in case of liver disease before taking this medicine.

Missed Doses

  • It is advisable not to miss a dose.
  • If you miss a scheduled dose of Sprycel tablets, contact your doctor immediately.

FAQs

This medicine is used for the treatment of blood cancer, and it helps to prevent the growth of cancer cells.


Reference

D., Cheng, H., Guo, J., Jiang, R.,Zhang, Y., Wan, C., Qin, J., Yuan, G., Chen, S., Yang, Z., Hu, J., Zhang, Y., & Li, W. (2023). 1-year results of dasatinib 70 mg/day versus 100 mg/day in newly diagnosed patients with chronic myeloid leukemia in chronic phase (CML‑CP): A prospective randomized controlled study. Hemasphere, 7(Suppl), e8560105. https://doi.org/10.1097/01.HS9.0000969568.85601.05


Silver, R. T., et al. (2006). Dasatinib (SPRYCEL®) 70 mg twice daily versus other dosing schedules in patients with imatinib-resistant or intolerant CML‑CP: Results from CA180‑034 (START‑C). Blood, 108(11), 166. https://doi.org/10.1182/blood.V108.11.166.166.


Kantarjian, H. M., et al. (2023). Low-dose dasatinib (50 mg daily) frontline therapy in newly diagnosed CML‑CP: 5‑year follow-up results. https://pubmed.ncbi.nlm.nih.gov/37308342/


Satadeve, P. (2025). Comparison of molecular response and safety of lower dose (70 mg) versus standard dose (100 mg) of generic dasatinib in newly diagnosed CML-CP: A randomized controlled study from India. Paper presented at the EHA 2025 Congress. https://www.cml-foundation.org/86-news-icmlf/2333-eha2025-daily-updates-3.html


Shah, N. P., Kantarjian, H., Kim, D.-W., Rea, D., Dorlhiac-Llacer, P., Milone, J. H., ... & Baccarani, M. (2008). Intermittent target inhibition with dasatinib 100 mg once Daily preserves efficacy and improves tolerability in imatinib-resistant and-intolerant chronic-phase chronic myeloid leukemia. Journal of Clinical Oncology, 26(19), 3204–3212. https://doi.org/10.1200/JCO.2007.14.8676

i
Trust & safety

Medical Disclaimer

Accurate, reviewed information to support informed healthcare decisions

For informational purposes only
Not a substitute for professional medical advice
Consult your doctor for diagnosis and treatment

Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.

The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.

This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.

Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.

Always follow advice from your doctor, pharmacist, or other licensed healthcare professional before starting, stopping, or changing any medicine or treatment.
Read full medical disclaimer in Terms & Conditions
Magicine PharmacopyCopyright 2026